Clinical study first step towards treating respiratory syncytial virusĀ
Drug Discovery World
OCTOBER 18, 2022
Enanta Pharmaceuticals, a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, has dosed the first subject in its Phase I clinical trial of EDP-323, a novel, oral L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV). .
Let's personalize your content